Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease

A compound of the Formula I:

• wherein W is
• provided that the bond between the —C(═X)— group and the W group may be attached at any available carbon atom within the W group as provided in R3, R6, and R15;
• X is O, or S;
• Each R1 is H, alkyl, cycloalkyl, halogenated alkyl, substituted phenyl, or substituted naphthyl;
• R2 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
• Z---Z′---Z″ is selected from the group consisting of O—C(R3)═C(R3), O—C(R3)2—C(R3)2, C(R3)2—O—C(R3)2, C(R3)═C(R3)—O, C(R3)2—C(R3)2–O, S—C(R3)═C(R3, S—C(R3)2—C(R3)2, C(R3)2—S—C(R3)2, C(R3)═C(R3)—S and C(R3)2—C(R3)2—S;
• Each R3 is independently a bond to the core molecule provided that only one R3 and no R6 or R15 is also said bond, H, F, Br, Cl, I, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, —CN, —NO2, —OR1, —C(O)N(R10)2, —NR1COR16, —N(R10)2, —SR1, —S(O)2R1, —C(O)R16, —CO2R1, aryl, R7, or R9;
• J, L, M, and Q are N or C(R6) provided that only one of J, L, M, or Q, is N and the others are C(R6), further provided that when the core molecule is attached to the pyridinyl moiety at M, Q is C(H), and further provided that there is only one attachment to the core molecule;
• G and Y are C(R6), provided that when the molecule is attached to the phenyl moiety at Y, G is CH;
• R4 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, R7, or R9;
• Each R5 is independently C1-3 alkyl or C2-4 alkenyl;
• Each R6 is independently H, F, Br, I, Cl, —CN, —CF3, —OR5, —SR5, or —N(R5)2, or a bond to the core molecule provided that only one R6 and no R3 or R15 is said bond,
• V is selected from the group consisting of O, S, and N(R4);
• R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1–3 heteroatoms independently selected from the group consisting of —O—, ═N—, —N(R19)—, and —S—, and having 0–1 substituent selected from R20 and further having 0–3 substituents independently selected from the group consisting of F, Cl, Br, and I, or R7 is a 9-membered fused-ring moiety having a 6-membered ring fused to a 5-membered ring and having the formula
• wherein E is O, S, or NR19,
• wherein E and G are independently selected from the group consisting of CR18, O, S, N, and NR19, and A is CR18 or N, or
• wherein E and G are independently selected from the group consisting of CR18, O, S, N, and NR19, and A is CR18 or N, each 9-membered fused-ring moiety having 0–1 substituent selected from R20 and further having 0–3 substituent(s) independently selected from the group consisting of F, Cl, Br, and I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;
• Each R8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, R7, R9, phenyl, or substituted phenyl;
• R9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1–3 heteroatoms selected from ═N— and having 0–1 substituent selected from R20 and 0–3 substituent(s) independently selected from the group consisting of F, Cl, Br, and I, or R9 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1–3 heteroatoms selected from ═N—, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0–1 substituent selected from R20 and 0–3 substituent(s) independently selected from the group consisting of F, Cl, Br, and I and having a bond directly or indirectly attached to the core molecule where valency allows;
• Each R10 is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from the group consisting of R13, cycloalkyl substituted with 1 substituent selected from R13, heterocycloalkyl substituted with 1 substituent selected from R13, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, and substituted phenyl;
• Each R11 is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;
• R13 is —OR11, —SR11, —NR11R11, —C(O)R11, —C(O)NR11R11, —CN, —CF3, —NR11C(O)R11, —S(O)2NR11R11, —NR11S(O)2R11, or —NO2;
• Each R15 is independently a bond to the core molecule provided that only one R15 and no R6 or R3 is also said bond, H, F, Br, Cl, I, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, —CN, —NO2, —OR1, —C(O)N(R10)2, —NR1COR16, —N(R10)2, —SR1, —CO2R1, aryl, R7, or R9;
• R16 is H, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, heterocycloalkyl, substituted heterocycloalkyl, substituted phenyl, or substituted naphthyl;
• Each R18 is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —OR11, —SR11, —NR11R11, —C(O)R11, —NO2, —C(O)NR11R11, —CN, —NR11C(O)R11, —S(O)2NR11R11, —NR11S(O)2R11, F, Cl, Br, I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0–1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —OR11, —SR11, —NR11R11, —C(O)R11, —NO2, —C(O)NR11R11, —CN, —NR11C(O)R11, —S(O)2NR11R11, or —NR11S(O)2R11, and further provided that the fused-ring moiety has 0–3 substituent(s) selected from F, Cl, Br, or I;
• R19 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, —SO2R8, or phenyl having 1 substituent selected from R20 and further having 0–3 substituents independently selected from F, Cl, Br, or I;
• R20 is alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR11, —SR11, —NR11R11, —C(O)R11, —C(O)NR11R11, —CN, —NR11C(O)R11, —S(O)2NR11R11, —NR11S(O)2R11, —NO2, alkyl substituted with 1–4 substituent(s) independently selected from the group consisting of F, Cl, Br, I, and R13, cycloalkyl substituted with 1–4 substituent(s) independently selected from the group consisting of F, Cl, Br, I, and R13, or heterocycloalkyl substituted with 1–4 substituent(s) independently selected from the group consisting of F, Cl, Br, I, and R13;
• or pharmaceutically acceptable salt, or racemic mixture thereof.